Clinical characterization of these mutations has identified del17p, TP53, and BIRC3 as markers of high-risk CLL, and NOTCH1 and/or SF3B1 as markers of intermediate risk [4]. This evidence concerns the gene SF3B1 and B-cell chronic lymphocytic leukemia.